The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data

Natansh D. Modi, Jin Quan Eugene Tan, Andrew Rowland, Bogda Koczwara, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins

Research output: Contribution to journalArticle

Abstract

Introduction: Beta-blockers (BB) are commonly used to manage cardiovascular disease and may have benefits in controlling complications of anti-HER2 therapies. This study aimed to evaluate the association of pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapy for advanced breast cancer (ABC). Materials and Methods: Data from clinical trials EMILIA, TH3RESA, MARIANNE, and CLEOPATRA was pooled. Cox proportional analysis was used to assess the association between pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapies. Results: Of the 2,777 patients with HER2 positive ABC, 266 were using a BB at the time of anti-HER2 therapy initiation. BB use was associated with worse overall survival (OS) (adjusted HR = 1.27, 95% CI: 1.04–1.55). Sensitivity analysis in patients with pre-existing cardiovascular disease (CVD) also indicated that BB use was associated with worse OS (1.29, 1.02–1.63). Conclusion: In large high-quality data, BB use at the time of anti-HER2 therapy initiation for ABC was independently associated with worse OS, regardless of CVD status. The finding is contrary to pre-study hypotheses and findings in other BC subtypes. Future research should aim to gain a deeper understanding of the effects of BBs on specific BC subtypes, cancer types, and cancer treatments.

Original languageEnglish
Article number1130
Number of pages6
JournalFrontiers in Oncology
Volume10
DOIs
Publication statusPublished - 14 Jul 2020

Bibliographical note

This is an open-access article distributed under the termsof the Creative Commons Attribution License (CC BY). The use, distribution orreproduction in other forums is permitted, provided the original author(s) and thecopyright owner(s) are credited and that the original publication in this journalis cited, in accordance with accepted academic practice. Nouse, distribution orreproduction is permitted which does not comply with these terms

Keywords

  • beta-blockers
  • breast cancer
  • HER2 positive
  • survival
  • targeted therapy

Fingerprint Dive into the research topics of 'The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data'. Together they form a unique fingerprint.

  • Cite this